GlassScriptPhysician profile
Christa H Hubert
NPI 1982908026
$2,545.03
in general payments reported to CMS, 2019-2025
29 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $394 · 2023: $713 · 2024: $392 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131 · Education: $19.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,131.18 |
| Education | $19.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.38 | 2022-2025 | |
| Janssen Biotech, INC. | $355.56 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.55 | 2022-2024 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $157.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $139.73 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.43 | 2022-2025 | Eohilia, Entyvio |
| Organon LLC | $92.17 | 2022-2024 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $78.25 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $66.80 | 2024-2025 | Ibsrela |
| Celgene Corporation | $60.61 | 2022-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $58.15 | 2024-2025 | Iqirvo |
| Pfizer INC. | $55.51 | 2023-2025 | |
| Daiichi Sankyo INC. | $51.25 | 2022-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $45.38 | 2023-2025 | Dupixent |
| Genzyme Corporation | $43.83 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $42.80 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $41.08 | 2023-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $39.59 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $31.31 | 2022-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $29.19 | 2022-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $27.82 | 2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $27.13 | 2025 | Givlaari |
| Mylan Institutional INC. | $19.76 | 2023 | Hulio |
| Nestle Healthcare Nutrition INC. | $19.59 | 2022 | |
| Celltrion USA INC. | $19.50 | 2023 | Yuflyma |
| Biocon Biologics INC | $18.22 | 2025 | Yesintek |
| Mallinckrodt Hospital Products INC. | $16.02 | 2025 | Terlivaz |
| Qol Medical, LLC | $15.75 | 2023 | Sucraid |
| Vivus LLC | $15.62 | 2025 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Hubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.